CLOSTRIDIUM DIFFICILE DIAGNOSTICS MARKET ANALYSIS

Clostridium Difficile Diagnostics Market, by Diagnostic Test (Enzyme Immunoassays, Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), Stool Test (GDH Antigen Test and Toxin A and B Test), Blood Test, Colonoscopy or Sigmoidoscopy and Others), by End User (Hospitals, Diagnostic Centers, Specialty Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5315
Pages :177
Formats :
Excel and PDF
Industry : Biotechnology

Clostridium Difficile Diagnostics MarketSize and Trends

Global clostridium difficile diagnostics market is estimated to be valued at US$ 838.05 million in 2022 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2022-2030).

Global Clostridium Difficile Diagnostics Market- Drivers

The increasing prevalence of clostridium difficile infection (CDI) is anticipated to boost the demand for its diagnosis, which is expected to drive the global clostridium difficile diagnostics market growth.

Moreover, increasing approval of diagnostics tests/assays by regulatory authorities is expected to drive the market growth over the forecast period.

Global Clostridium Difficile Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets.

Global Clostridium Difficile Diagnostics Market: Key Developments

In 2021, the two German companies, Novatec Immundiagnostica GmbH and Virotech Diagnostics GmbH, collaborated to form Gold Standard Diagnostics Europe. The newly formed company is focusing on both human and veterinary markets, as it is manufacturing diagnostic kits for infectious diseases (bacterial, viral, and parasitic diseases), hormones, and autoimmunity.